This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LOS ANGELES, Nov. 13, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has recently closed four new payor contracts with national Preferred Provider Organization ("PPO") networks. The four new provider agreements are with:
America's Choice Provider Network, LLC
Galaxy Health Network
Prime Health Services, Inc.
By entering into these PPO network agreements, the full suite of Response Genetics' precision genetics services are now offered to the health plans, self-insured employers, third party administrators and other clients that participate in these networks. In total, these new contractual relationships allow Response Genetics access to an additional 54 million people spread throughout the United States. With these latest PPO network contracts, Response Genetics has now entered into a total of six PPO network contracts this year opening access to over 135 million Americans.
Response Genetics' predictive genomic testing is primarily targeted to patients battling lung, colon, gastric, and melanoma cancers. The results generated from Response Genetics' testing services provide treating physicians actionable information that guides therapeutic decisions enabling the best therapy on a specific patient's tumor. The precise nature of Response Genetics' services brings a value proposition that is expected to improve patient outcomes, enhance efficiencies and ultimately reduce costs associated with optimal health care delivery.
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit
About America's Choice Provider Network, LLC
America's Choice Provider Network, LLC ("ACPN") is a National Healthcare Savings Provider Network that has developed its own network and technology. ACPN is dedicated to finding solutions to assist every party in healthcare transactions. ACPN and its experienced team is committed to creating solutions in the healthcare industry as it relates to the millions of claims that fall out-of-network each month.